Myelodysplastic syndrome (deletion 5q) - lenalidomide [ID480]: evaluation report


01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - Celgene

03. Consultee comments on the ACD - MDS UK and Leukaemia Care

04. Consultee comments on the ACD- RCP and British Committee for Standards in Haematology

05. Public comments on the ACD received through the NICE website

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 19 August 2014